Ipamorelin stimulates growth hormone release, but no robust benefit for muscle, fat loss or anti-aging has been established in healthy adults, alone or with CJC-1295. No validated stack dosage or corresponding medicinal product in the French database has been identified, and both substances are prohibited at all times by WADA.
The promise of “physiological” stimulation sells better recovery and slower aging. The mechanism exists; the clinical outcome remains to be demonstrated.
The factual answer is much shorter: these peptides do stimulate the GH-IGF-1 axis, but no clinical efficacy has been demonstrated in healthy humans for strength, body recomposition, recovery or anti-aging. CJC-1295 with DAC has been studied in small pharmacological trials. Ipamorelin has mainly been studied for acute GH secretion and in a negative trial on postoperative ileus. Their combination has no validated dosage or cycle.
In France, neither product has an identified authorization for these uses. Their availability in a “research chemicals” store constitutes neither legal marketing as a medicine nor a guarantee of sterility. The case of retatrutide, between French trials and online sales, helps distinguish these two channels.
GH, IGF-1 and aging: a decline is not necessarily a deficiency
Growth hormone, or GH, is released by the pituitary gland in pulses, especially during deep sleep. It acts directly on certain tissues and stimulates IGF-1 production, notably in the liver. This axis contributes to growth, tissue renewal, protein metabolism and fat mobilization.
With age, GH peaks and IGF-1 decline on average. The marketing shortcut is to call this change a “deficiency” and then try to restore youthful levels. But a genuine GH deficiency is an endocrinological diagnosis. An age-related decline does not demonstrate that chronic stimulation improves health or longevity.
The strongest warning comes from trials of GH itself. A systematic review involving 220 healthy older adults found approximately 2 kg more lean mass and 2 kg less fat mass, without overall weight loss. Edema, joint pain, carpal tunnel syndrome and blood glucose disturbances were more common. In physically fit young adults, another review found increased lean mass, but no convincing improvement in strength or exercise capacity. Some of that “lean mass” may reflect water retention, not new contractile muscle.
These results do not prove that ipamorelin reproduces all the effects of injectable GH. They show why raising GH or IGF-1 is not in itself a favorable clinical outcome.
Ipamorelin: a GH secretagogue, not miniature GH
Ipamorelin is a synthetic pentapeptide that activates the GHSR-1a receptor, also called the GH secretagogue receptor or ghrelin receptor. Activation of this receptor in the hypothalamus and pituitary triggers the release of endogenous GH.
In the 1999 pharmacokinetic study, five exposure levels were administered by intravenous infusion to groups of eight healthy men. All exposures triggered a GH pulse, peaking around 40 minutes before returning to negligible concentrations. Ipamorelin’s terminal half-life was close to two hours. The study measured neither muscle gain, fat loss, sleep nor recovery.
The expression “selective secretagogue” comes from an earlier paper showing strong GH release without a notable increase in ACTH or cortisol in pigs, unlike GHRP-2 and GHRP-6. This selectivity is plausible and discussed in the 2026 endocrinology review. However, it remains based on preclinical and acute human data, not months of self-administration.
A randomized phase II clinical trial recruited 117 patients following bowel resection, including 114 in the modified safety and efficacy analyses. Ipamorelin did not significantly accelerate tolerance of a solid meal compared with placebo. This hospitalized population and digestive endpoint provide no information about performance or anti-aging.
CJC-1295: why DAC completely changes exposure
CJC-1295 is an analogue of GHRH, the hypothalamic hormone that stimulates the pituitary GHRH receptor. It therefore does not activate the same receptor as ipamorelin.
The version studied in humans contains a Drug Affinity Complex, or DAC. This modification creates a bond with circulating albumin and greatly prolongs exposure. In the two randomized trials by Teichman and colleagues in healthy adults, a single administration increased mean GH 2- to 10-fold for at least six days and IGF-1 1.5- to 3-fold for 9 to 11 days. The estimated half-life reached 5.8 to 8.1 days, with a cumulative effect after repeated administrations.
This result proves a lasting pharmacological action. It does not prove improved body composition. The trials, conducted over 28 or 49 days, were designed to measure pharmacokinetics, GH, IGF-1 and tolerability, not strength, visceral fat, injuries or aging.
“Without DAC” often means a different molecule
Sellers use “CJC-1295 without DAC” to refer to a short-acting analogue generally called Mod GRF 1-29. The 2026 review found no published human clinical study directly evaluating this product. Its duration of action, effective dose and safety cannot be inferred from CJC-1295 with DAC.
A label that says only “CJC-1295” therefore leaves a fundamental question unanswered: does it contain the long-acting compound with DAC, Mod GRF 1-29, another sequence or a misidentified product? This confusion alone makes it impossible to interpret a testimonial or adverse effect.
Ipamorelin alone or a CJC-1295 stack: a useful comparison
The argument for the stack rests on two different routes to GH release. CJC-1295 activates the GHRH receptor. Ipamorelin activates GHSR-1a. Research on other GHRHs and GHRPs makes a stronger GH response plausible when they are combined.
But synergy in secretion does not demonstrate synergy in benefit. No controlled trial has evaluated the ipamorelin-CJC-1295 stack in healthy adults.
| Option | Expected biological signal | Direct human data | What is missing |
|---|---|---|---|
| Ipamorelin alone | Relatively brief GH peak via GHSR-1a | Acute pharmacology study and negative postoperative trial | Muscle, fat, strength, sleep and extended safety data |
| CJC-1295 with DAC | Prolonged elevation of GH and IGF-1 | Small phase I trials in healthy adults | Clinical efficacy and long-term safety |
| “CJC-1295 without DAC” | Presumed shorter peak via the GHRH receptor | No direct clinical study identified | Pharmacokinetics, efficacy, dose and safety |
| Ipamorelin + CJC-1295 | Stimulation of two complementary receptors | No controlled trial of the stack | Any clinical outcome, dosage and cycle |
| Sermorelin | Short-acting GHRH analogue historically used in pediatrics in the United States | Older diagnostic and pediatric data | No validated benefit for anti-aging or performance |
| GHRP-2, GHRP-6, hexarelin | GH with more ghrelin-related effects or cross-hormonal activation | Acute endocrine studies | Athletic benefit, extended safety data, hormonal specificity |
The term “stack” gives the impression of an optimized formula. Here, it mainly means piling two uncertainties on top of each other, with potentially greater hormonal exposure.
What dosage of ipamorelin or CJC-1295 is validated?
Published doses come from three incompatible worlds: acute phase I infusions, short studies under clinical supervision and unverifiable forum practices. Turning them into a self-injection schedule would be a dangerous extrapolation.
Here is what the data actually support:
- ipamorelin shows a dose-response relationship for an acute GH peak in an intravenous study
- CJC-1295 with DAC accumulates and keeps IGF-1 elevated for several days in small trials
- the “without DAC” version has no published human clinical pharmacokinetic data
- no trial has compared different cycles for muscle, fat or recovery outcomes
- no efficacy-based stopping rule has been validated in healthy humans
So I will not reproduce injection schedules from forums. They are not medical dosages and could facilitate the use of unauthorized injectables whose actual identity is uncertain. The answer to “which cycle should I choose?” is: no validated cycle exists.
An IGF-1 blood test does not fix this problem. It can show that the axis has been stimulated, but it verifies neither the molecule in the vial, sterility, the absence of endotoxins nor a clinical benefit.
What human studies show, and what they do not
The two reviews published in 2026 converge on the same hierarchy. GH-IGF-1 axis peptides are visible in sporting communities, but their actual prevalence remains unknown. Studies mainly focus on biomarkers or specific medical indications, not the stacks used in bodybuilding.
The evidence can be summarized as follows:
- pharmacological evidence, ipamorelin triggers a GH peak and CJC-1295 DAC produces a sustained increase in GH and IGF-1
- evidence of recomposition, absent for these two products in healthy humans
- evidence of performance benefits, absent for strength, power or aerobic capacity
- evidence of recovery benefits, absent for injuries, pain or return to training
- anti-aging evidence, absent for frailty, function, disease or mortality
- safety, limited to short exposures, small samples and pharmaceutical-quality products
Positive reviews posted online may reflect water retention, training changes, dietary changes, a placebo effect or concurrent anabolic steroid use. Without a comparator and an authenticated product, they cannot attribute the result to the advertised peptide.
Risks: prolactin, blood glucose, retention and IGF-1 signaling
Prolactin and cortisol: do not lump the whole family together
Elevations in prolactin, ACTH and cortisol are better documented with GHRP-2, GHRP-6 and hexarelin. Ipamorelin appears to have less effect on these hormones in the available data. Claiming that it “raises prolactin” in all users would therefore be excessive.
The opposite mistake would be to infer proven safety. Ipamorelin studies are short, and the contents of a gray-market vial may not match its label. An abnormal hormone panel after a stack also cannot identify which product, excipient or concurrently used substance is responsible.
Blood glucose and soft tissues
Prolonged GH stimulation may reduce insulin sensitivity. The 2026 review identifies dysglycemia as a class safety signal, with intensity varying by molecule and exposure. Possible consequences of somatotropic activation also include water retention, swelling, paresthesia, muscle or joint pain and carpal tunnel syndrome.
The short CJC-1295 trials reported no serious events under their controlled conditions. The FDA nevertheless reports serious events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction. For ipamorelin, it mentions aggregates, impurities and immunogenicity risk, as well as serious events, including deaths, in the literature on postoperative intravenous administration. This signal does not allow those deaths to be attributed to the peptide or the risk of another use to be quantified. The agency highlights insufficient data for certain other injectable routes.
Cancer: plausible risk, unproven causality
IGF-1 activates pathways involved in cell proliferation and survival. In the UK Biobank, higher circulating concentrations were associated with a slightly higher risk of several cancers, with relationships varying by organ. This observation demonstrates neither that IGF-1 causes these cancers nor that CJC-1295 causes them.
The signal remains concerning because no long-term trial has studied these peptides in people with a history of cancer, a precancerous lesion or high susceptibility. Calling them “carcinogenic peptides” would be wrong. Presenting a chronic elevation of IGF-1 as harmless would be wrong too.
The separate risk posed by the vial
An injectable product adds identity, content, sterility, endotoxins, particles and stability to the pharmacological unknowns. In 2026, the ANSM received several reports involving fraudulent peptides, with hospitalizations, injection-site infections and severe allergic reactions.
Our investigation into online peptides, contamination and the limits of certificates of analysis · FR explains why “99% HPLC purity” does not prove that a vial is suitable for injection.
Status in France and doping: available does not mean authorized
As of October 13, 2026, no entry for ipamorelin, ipamoréline or CJC-1295 was found in the official medicinal product and composition files of the Public Medicines Database, updated on September 29. The database covers medicines marketed or previously marketed during the last three years in France, not all historical authorizations. The Frontiers in Endocrinology review states that no CJC-1295 variant is approved by major authorities, including the FDA and EMA. No French anti-aging, sporting or cosmetic indication has been identified for these two peptides.
The ANSM gives more directly applicable advice:
- do not buy peptides online, on social media or from acquaintances
- do not inject a product that was not prescribed and obtained from a pharmacy
- never use a product marked “research use only” or “not for human use”
In France, only nonprescription medicines may be sold online by authorized pharmacies. A foreign research product store is not a shortcut to a prescription.
The sporting framework is even clearer. The 2026 WADA list in force names CJC-1295 and ipamorelin under S2.2.4, among GH-releasing factors and secretagogues prohibited at all times, in and out of competition. An occasional injection or a product advertised as DAC-free does not bypass this classification. An athlete subject to the World Anti-Doping Code therefore risks a violation even out of competition.
Here are the useful distinctions:
| Question | Ipamorelin and CJC-1295 |
|---|---|
| Medicine found in the French database consulted? | None, within the stated scope |
| US compounded preparation = French marketing authorization? | No: separate frameworks and authorities |
| Stack dosage validated for bodybuilding? | No controlled trial identified for this objective |
| WADA 2026 anti-doping rules | S2.2.4, prohibited at all times |
A regulatory change in the United States would not automatically change the French situation. Our overview of peptides and FDA regulation in 2026 · FR details the difference between compounding, approval and European authorization.
If you have already used them: reduce risk without optimizing the stack
This article does not replace a medical consultation. If you already use a product obtained outside authorized channels, the prudent step is to stop it and not test another vial for comparison.
Prepare this information for your doctor:
- a photograph of the vial, label and batch number
- the advertised name, presumed presence of DAC and stated quantity
- dates and times of use
- other peptides, hormones, anabolic steroids, stimulants and supplements
- a timeline of symptoms
- the certificate of analysis, without presenting it as proof of identity
Seek medical advice promptly for persistent palpitations, significant swelling, new tingling, unusual headaches, thirst and very frequent urination, a spreading local reaction, fever or feeling unwell. Call 15 or 112 for chest pain, difficulty breathing, loss of consciousness, confusion or a severe allergic reaction.
Do not try to correct abnormal blood glucose, prolactin or IGF-1 with another product. The assessment must first distinguish a transient effect, another substance, a pre-existing illness and an emergency.
To compare these findings with other promises in this family, the guide peptides in bodybuilding: effects and risks distinguishes biomarkers from performance. The dossier GHRP-6: evidence and French regulatory status helps explain why two secretagogues do not necessarily share the same tolerability.
Le Biohacker’s take
Ipamorelin is a short-acting and relatively selective secretagogue. CJC-1295 with DAC is a long-acting GHRH analogue that can keep GH and IGF-1 elevated for several days. Their mechanism is real. Their anti-aging and sporting reputation is not supported by demonstrated clinical benefits for these objectives.
The most misleading point is dosing. Precise numbers circulate, but none corresponds to a validated stack cycle in healthy humans. The “without DAC” product does not even have published direct clinical data. Adding ipamorelin does not turn this lack of evidence into a protocol.
My view is therefore against self-administration. The expected benefit remains speculative, while hormonal exposure, blood glucose risk, soft-tissue effects, oncological uncertainty, doping and vial quality all add up. A peptide that shifts a biomarker is not automatically a health tool. In this case, it is mainly an endocrine experiment without an established clinical outcome.
